Deramiocel Now Asks the FDA to Protect Arm Function in Duchenne, With a Decision Due November 22nd

Lifting a fork to his mouth, pushing the joystick on a power wheelchair, holding a phone long enough to text a friend: for a teenager with Duchenne muscular dystrophy who no longer walks, those are the movements that keep him independent, and every year the disease takes a little more of them. On November 22nd the FDA is due to decide whether deramiocel, a cell therapy from Capricor Therapeutics, can be approved to slow that loss. No FDA-approved Duchenne medicine today has a label written around arm and hand function.

Deramiocel did not arrive at this decision in a straight line. The FDA turned down Capricor's first application in July 2025. Its own advisers voted 9 to 3 in July 2026 that the evidence did not show deramiocel works for Duchenne heart disease, the use Capricor first asked for. Capricor then narrowed the request to upper limb function, the main measure of its Phase 3 trial, and the FDA added 3 months to review it. Families are now waiting on a decision built on a trial the company calls a success and the agency's reviewers question.

What the FDA Decides About Deramiocel for Duchenne on November 22nd

The FDA's November 22, 2026 goal date (its PDUFA date) covers Capricor's request to approve deramiocel, also known as CAP-1002, for upper limb function in Duchenne muscular dystrophy, the refined indication Capricor submitted in August 2026 together with 24-month data from its HOPE-3 trial. The FDA classified that submission as a major amendment and moved the goal date from August 22nd, according to Capricor's August 24th announcement, which also said the agency accepted the amendment citing the significant unmet need in Duchenne.

Deramiocel is made from cardiosphere-derived cells, grown from donated human heart tissue and given by IV infusion every 3 months. The cells come from donated hearts rather than from the boy himself, and because the treatment does not depend on his mutation, it is not limited to a single exon. Capricor says the cells release exosomes, tiny packets that shift inflammatory immune cells toward a healing state. It does not restore dystrophin, the protein missing in Duchenne, and in HOPE-3 it was given on top of steroids.

The goal date is a deadline, not a promise. The FDA can act before it, and it can also reject, approve with a narrower label, or ask for more data. The deramiocel FDA calendar page will show the outcome the day it is public.

Once a boy with Duchenne stops walking, his arms carry his independence, from feeding himself to driving a power wheelchair, and they are what deramiocel's application is now about. Most of what families hear about Duchenne treatment is measured in walking: how far a boy can go in 6 minutes, how fast he rises from the floor. After he stops walking, those tests no longer apply, and the trials and labels built on them say little about what comes next. Arm strength goes from the shoulders down. Researchers who use the upper limb test describe weakness that shows first at the shoulder, often while a boy still walks, and then reaches the elbow and the hand after walking ends, which is when lifting a hand to his mouth and then the finer finger movements he uses on a phone or a joystick start to slip.

“Their arms are how they feed themselves, control their wheelchairs and use their phones”

Craig McDonald, MD, HOPE-3 principal investigator at UC Davis Health, in Capricor's October 5, 2026 announcement

Clinics measure that loss with the Performance of the Upper Limb test, version 2.0, scored from 0 to 42 across 3 levels: shoulder (up to 12 points), elbow (up to 17) and wrist and hand (up to 13), as Brogna and colleagues describe it in PLOS One in 2018. In HOPE-3's own placebo group, young men lost about 2 to 3 points in a year, depending on how it is measured. Two points can sound small, yet on a 42-point scale built from everyday reaches, a couple of points can mean one of those reaches moving out of his range.

What the HOPE-3 Trial Showed for Deramiocel, and Why the FDA Questions It

Deramiocel's Phase 3 trial, HOPE-3, met its main arm-function goal by Capricor's analysis and missed it by the FDA's reading of the original plan, and that disagreement is what the FDA must settle. HOPE-3 gave deramiocel or a placebo every 3 months for a year to 106 boys and young men aged 10 to 22 at 20 U.S. sites. The FDA's briefing document describes them as mostly non-walking, with an average age of 15. Capricor reported that deramiocel slowed the decline in PUL 2.0 by 54% compared with placebo (p=0.029), and The Lancet published those results in July 2026.

The FDA's reviewers read the same trial differently. Their July 2026 briefing document says HOPE-3 did not meet its pre-specified primary and secondary endpoints, and that the statistical analysis plan was changed after the double-blind year ended, with the final version dated 1 day before the data were unblinded and not agreed with the FDA in advance. It also notes that hypersensitivity reactions were far more common on deramiocel, 22 of 53 participants against 8 of 52 on placebo, which the FDA said raises the possibility that families and staff could guess who was getting the drug. On how much the results shifted depending on how missing data were handled, the briefing document was blunt.

“raises serious questions about whether there is substantial evidence of effectiveness”

FDA briefing document for the July 29, 2026 advisory committee meeting

Capricor disputes that reading. Its CEO, Linda Marbán, said before the meeting that the company's results are governed by its final analysis plan, version 3.0, finalized before unblinding, and that the FDA's alternative analyses rely on an incomplete earlier draft. The Lancet published the trial under the company's plan. The heart result is where the two sides sit furthest apart. Capricor's July 29, 2026 announcement describes clinically meaningful benefits in several heart measures, while the FDA's briefing document counts heart pumping (left ventricular ejection fraction) among the pre-specified endpoints the trial did not meet, and the advisory committee voted 9 to 3 against the heart claim.

Deramiocel's 2-Year Data, the Same Boys Before and After Treatment

Capricor's newest evidence comes from what happened after the blinded year, when 98 of the 106 participants continued on deramiocel in an open-label extension. Boys who had spent year 1 on placebo lost 2.05 PUL 2.0 points that year and 0.49 points in their first year on deramiocel, a 76% smaller decline, according to Capricor's October 5, 2026 announcement of its World Muscle Society poster. Boys who started on deramiocel lost 0.95 points in year 1 and 0.89 in year 2.

Dr. McDonald put the case plainly in Capricor's announcement, calling following the same young man before and after treatment a powerful way to see an effect, and adding a phrase families will recognize from clinic, "Time is muscle." The open question for the FDA is whether an unblinded comparison, layered on a blinded year whose analysis it disputes, adds up to the substantial evidence the law requires. Capricor says the FDA received these data, along with additional robustness analyses, as part of the amendment it is now reviewing.

Deramiocel Side Effects Families Should Know About

Infusion reactions are the side effect that stands out for deramiocel. In HOPE-3 the FDA counted hypersensitivity reactions, a broad group that includes allergic-type reactions, rash, flushing, fever and a fast heart rate, in about 42% of participants on deramiocel against about 15% on placebo, and 11 placebo participants who had none during the blinded year developed one after switching to deramiocel. The FDA's briefing document also describes a placebo participant who had a life-threatening allergic reaction (anaphylaxis) at his first infusion, which the FDA said may have been linked to the product's other ingredients, and it lists hypersensitivity reactions including anaphylaxis among deramiocel's risks. In the earlier HOPE-2 trial, 1 participant had a severe allergic reaction during his second infusion that was treated with epinephrine and an overnight hospital stay for observation, and he stopped treatment; the trial then added steroid and antihistamine premedication before each infusion. Capricor reports about 1,300 infusions across more than 200 people with Duchenne and describes the long-term safety experience as consistent. Until there is an FDA label, the full list of warnings and how infusions would be managed is not known.

What a Boy With Duchenne Who No Longer Walks Can Be Prescribed Today

A boy with Duchenne who no longer walks can be prescribed 3 FDA-approved Duchenne medicines whatever his mutation, the steroids Agamree and deflazacort and the HDAC inhibitor Duvyzat, plus an exon-skipping drug if his mutation fits one. Eight medicines are FDA-approved to treat Duchenne muscular dystrophy, and 2 questions decide which of them a non-walking teenager can use. The first is whether the label is limited to a single mutation, which rules out the 4 exon-skipping drugs unless his mutation fits one of them. The second is whether the label requires that he can still walk, which only the gene therapy Elevidys's label does; the exon-skipping labels have no walking limit. Three remain, 2 steroids and givinostat, and the labels for Agamree and Duvyzat say their main trials enrolled boys who could still walk.

That does not make these medicines wrong for a boy who has stopped walking. The international Duchenne care considerations recommend continuing steroids after walking ends, and the Duvyzat label has no walking requirement. What the sieve shows is narrower, and it is the gap deramiocel's application sits in: much of the evidence behind today's labels comes from boys who could still walk, and no label is written around keeping the arms working.

Duchenne Clinical Trials Open to Boys Who No Longer Walk

Of the Duchenne studies open or about to open on ClinicalTrials.gov, 31 test a medicine, gene therapy, cell therapy or supplement, and 5 of those 31 let a boy who no longer walks into at least 1 group. Sixteen require that he can walk, and 10 set no walking rule in their listed criteria. Trial Friend read the eligibility criteria of each of the 31 on October 15, 2026, starting from the same search as our Duchenne trials page.

Three of the trials with no walking rule test heart treatments, an empagliflozin study in the United Kingdom, an SGLT2 inhibitor study at Vanderbilt and a SERCA2a gene therapy for adults, and they matter for the same young men deramiocel's heart claim was meant to help. Heart disease is a leading cause of death in Duchenne, and the care considerations call for regular heart imaging and starting heart medicines early, advice that stands whatever the FDA decides about deramiocel.

How Families Can Prepare for the Deramiocel Decision

After the July panel vote, Paul Melmeyer of the Muscular Dystrophy Association said the families who testified made clear that muscle and heart function keep declining and "families cannot get that time back." Parent Project Muscular Dystrophy has called for a comprehensive and timely review. The decision is the FDA's, but a few steps now mean a family is ready for either answer.

Ask for a PUL 2.0 at the next neuromuscular visit, and ask for the shoulder, elbow and hand scores, not only the total. A dated score shows where his arms are today, which helps his doctors judge any new treatment, and it cannot be recreated later. Ask the clinic too whether your son would fit the requested indication, since the label, if there is one, will say exactly who qualifies.

Bring up the heart separately. The advisory committee's vote was about whether deramiocel treats Duchenne cardiomyopathy, not about whether heart care matters, and nothing in this decision changes the guideline advice on heart monitoring. Ask when his last heart scan was and whether he should be on heart medicines already.

Look at the 5 open trials above with his neuromuscular team, particularly the 3 with US sites, and ask what he would give up by enrolling, since some gene therapy trials exclude boys who have had other experimental treatments. Our Duchenne treatment guide covers the exon-skipping drugs if his mutation fits one.

Questions Duchenne Families Ask About Deramiocel